UB-941 is under clinical development by UBI Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UB-941’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UB-941 overview
UB-941 (DCBCO0902) is under development for the treatment of malignant melanoma, colon cancer, lung cancer, thyroid cancer, ovarian cancer and other cancer cells harboring BRAF gene mutations. The drug candidate is administered through oral route in the form of tablet. It acts by targeting B-Raf kinase.
UBI Pharma overview
UBI Pharma. is a drug development business. Monoclonal antibody medications, protein pharmaceuticals, small molecule drug development, and other integrated pharmaceutical products are developed by the company. The company is headquartered in Hsinchu,
For a complete picture of UB-941’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.